Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

38.97 +0.57 (+1.48%)
Streaming Delayed Price Updated: 3:26 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
39 40 Next >
Current Analysis: GSK Plc
In the pharmaceutical industry, GSK PLC ranks as one of the largest companies by total sales. 
Via Talk Markets
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to... 
Via Benzinga
Topics Intellectual Property Lawsuit
European Drug Regulator Recommends Approval Of GSK's Bone Marrow Cancer Med
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a posi 
Via Benzinga
GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
From GSK plc
Via Business Wire
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Peering Into GSK's Recent Short Interest
Via Benzinga
Price Over Earnings Overview: GSK
Via Benzinga
6 Nasdaq 100 Stocks Down 40% or More that Will Soar As Much 367%
Wall Street is forever optimistic about the future for stocks and pegs these seven Nasdaq 100 stocks as ready for supersonic growth 
Via InvestorPlace
GSK is a remedy for the winter investment blahs
Pharma stock GSK is a remedy for the winter blahs with a low beta, a high yield, and value for investors. Sales of new drug Arexvy underpin results. 
Via MarketBeat
Topics Intellectual Property
3 Healthcare Stocks Getting Help From the Aging Population
America's aging population needs chronic conditions treatments, and these healthcare stocks are growing in the quest for healing solutions. 
Via InvestorPlace
3 Top Dividend Stock Picks for Steady Income and Capital Appreciation
Conservative investors will benefit from these top dividend stock picks that are likely to generate significant returns. 
Via InvestorPlace
Moderna Beats Sales Forecasts, But Light Guidance Could Rattle Shares
The company issued below-consensus sales views for 2023 and 2024. 
Via Investor's Business Daily
GSK Hikes Guidance On The Back Of Its Strong RSV Vaccine Launch
The company is rivaling Pfizer, which also gained approval this year for an RSV vaccine. 
Via Investor's Business Daily
GSK Lifts Annual Guidance Again Helped By Strong Launch Of RSV Vaccine, Steady Demand For Shingles Shot
GSK plc (NYSE: GSK) reported Q3 FY23 s 
Via Benzinga
Nasdaq, S&P 500 Futures Slide Ahead Of Fed Decision, Economic Data: Analyst Tells Why November Could Herald 'Good News'
U.S. stocks could start Wednesday's session lower as traders stay cautious ahead of the Fed decision and more earnings. 
Via Benzinga
Topics Economy Stocks
Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK
GSK plc (NYSE: GSK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have  
Via Benzinga
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
Hope for Endometrial Cancer - GSK Drug Proves Effective in Increasing Survival Rates
GSK plc (NYSE: GSK)  
Via Benzinga
GSK's Competitive Edge, Surpasses Pfizer in Respiratory Syncytial Virus Vaccine Sales
GSK (NYSE: GSK) has reportedly taken an early lead in the race for respiratory syncytial virus (RSV) vaccine dominance, surpassing Pfizer Inc (NYSE: PFE), which previously dominated the COVID-19... 
Via Benzinga
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe... 
From 23andMe, Inc.
Via GlobeNewswire
Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal
Hansoh Pharma sold ex-China rights for its B7-H4 ADC to GSK in a $1.57 billion deal. Meanwhile, OrbiMed has raised $4.3 billion in commitments for three healthcare funds, including $751 million for its... 
Via Talk Markets
3 Bill Gates Stocks to Buy for Billionaire-Like Returns
Microsoft and Berkshire Hathaway are the two most popular Bill Gates stocks. Investors know these three others far less. 
Via InvestorPlace
3 Deeply Undervalued Growth Stocks
As in 2022, the current downturn of stocks appears to be way overdone, making this a good time to buy undervalued growth stocks. 
Via InvestorPlace
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
From Alector, Inc.
Via GlobeNewswire
New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
From GSK plc
Via Business Wire
Bank Of America, Mastercard, NRA And Others Are Lobbying For Cannabis Banking Reform — Who Knew?
Several entities have included the Secure and Fair Enforcement Regulation (SAFER) Banking Act on their lobbying disclosures for the third quarter of 2023. 
Via Benzinga
Topics Cannabis
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with... 
Via Talk Markets
GSK: Pharma Giant Prioritizing Shareholder Dividends
A good hunting ground for dividend stocks is often companies from which Wall Street wants to see strong performance in the short-term, while its long-term prospects are actually what are most bright. 
Via Talk Markets
Google AI-Powered Chatbot's Ethical Concerns, MGM Hackers Waited For Days Before Issuing Financial Demands, Costco Accused Of Sharing Confidential Health Data With Facebook: Today's Top Stories
Bloomberg Google's AI Dilemma - Bard's Promise Versus Ethical Concerns 
Via Benzinga
Topics Artificial Intelligence Hacking
Little Less Heartburn For GSK: Settles Another California Lawsuit On Zantac
GSK plc (NYSE: GSK) has reached a confidential settlement in the Cantlay/Harper case filed in California state court.  
Via Benzinga
Topics Lawsuit
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.